

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2003201618 B2**

(54) Title
Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumours

(51) International Patent Classification(s)
A61K 38/17 (2006.01) **A61K 31/728** (2006.01)
A61K 31/282 (2006.01) **A61K 31/729** (2006.01)
A61K 31/475 (2006.01) **A61K 31/732** (2006.01)
A61K 31/513 (2006.01) **A61K 31/734** (2006.01)
A61K 31/519 (2006.01) **A61K 31/765** (2006.01)
A61K 31/675 (2006.01) **A61K 31/785** (2006.01)
A61K 31/704 (2006.01) **A61K 31/795** (2006.01)
A61K 31/7048 (2006.01) **A61L 31/04** (2006.01)
A61K 31/715 (2006.01) **A61P 9/00** (2006.01)
A61K 31/717 (2006.01) **A61P 35/00** (2006.01)
A61K 31/722 (2006.01)

(21) Application No: **2003201618** (22) Date of Filing: **2003.01.07**

(87) WIPO No: **WO03/057203**

(30) Priority Data

| | | |
|----------------------|-------------------|--------------|
| (31) Number | (32) Date | (33) Country |
| PD2002A000003 | 2002.01.11 | IT |

(43) Publication Date: **2003.07.24**

(43) Publication Journal Date: **2003.09.04**

(44) Accepted Journal Date: **2008.11.06**

(71) Applicant(s)
Fidia Farmaceutici S.p.A.;Deutsches Krebsforschungszentrum (DKFZ)

(72) Inventor(s)
Stark, Hans-Jurgen;Fusenig, Norbert E;Willhauck, Michael;Pavesio, Alessandra

(74) Agent / Attorney
Lord and Company, 4 Douro Place, West Perth, WA, 6005

(56) Related Art
WO 2002/018450 A, 7 March 2002
WO 1999/061080 A, 2 December 1999
WO 2000/001733 A, 13 January 2000
WO 2002/018448 A, 7 March 2002
WO 2000/054762 A, 21 September 2000
US 5520916 A, 28 May 1996
EP 0341745 A, 15 November 1989
WO 2002/041877 A, 30 May 2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 2003/057203 A3

- (51) International Patent Classification⁷: **A61L 27/00**,
A61P 35/00, A61K 47/36
- (74) Agents: MINOJA, Fabrizio et al.; Bianchetti Bracco Mi-
noja S.r.l., Via Rossini, 8, I-20122 Milano (IT).
- (21) International Application Number:
PCT/EP2003/000078
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LI, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 7 January 2003 (07.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PD2002A000003 11 January 2002 (11.01.2002) IT
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants (*for all designated States except US*): **FIDIA
FARMACEUTICI S.P.A.** [IT/IT]; Via Ponte della Fab-
brica, 3/A, I-35031 Abano Terme (IT). **DEUTSCHES
KREBSFORSCHUNGSZENTRUM (DKFZ)** [DE/DE];
Im Neuenheimer Feld 280, 69120 Heidelberg (DE).
- Published:
— with international search report
- (72) Inventors; and
- (88) Date of publication of the international search report:
31 December 2003
- (75) Inventors/Applicants (*for US only*): **FUSENIG, Nor-
bert, E.** [DE/DE]; Am Pferchelhang 32, 69118 Heidelberg
(DE). **STARK, Hans-Jürgen** [DE/DE]; Am Plötzberg
16, 74909 Meckesheim (DE). **WILLHAUCK, Michael**
[DE/DE]; Rollbühlstrasse 58A, 68309 Mannheim (DE).
PAVESIO, Alessandra [IT/IT]; Riviera Paleocapa, 9,
I-35141 Padova (IT).
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: BIOMATERIALS BASED ON HYALURONIC ACID FOR THE ANTI-ANGIOGENIC THERAPY IN THE TREAT-
MENT OF TUMOURS

(57) Abstract: The use in the medical-surgical field of biomaterials based on hyaluronic acid derivatives, optionally in association
with natural, synthetic or semisynthetic biopolymers, for suppressing the angiogenic process associated with tumour proliferation
(in primary and secondary tumours) is disclosed.



WO 2003/057203 A3

**BIOMATERIALS BASED ON HYALURONIC ACID FOR THE ANTI-
ANGIOGENIC THERAPY IN THE TREATMENT OF TUMOURS**

SUBJECT OF THE INVENTION

The present invention relates to the use in the medical-surgical field of biomaterials based on hyaluronic acid derivatives, optionally in association with natural, synthetic or semisynthetic biopolymers, for suppressing the
5 angiogenic process associated with tumour proliferation (in primary and secondary tumours).

BACKGROUND OF THE INVENTION

The induction and development of angiogenesis is a pre-requisite for the development of a primary tumour, and for any subsequent metastases.

10 Angiogenesis is a dynamic process closely linked with the proliferation of cancer cells, because it is the latter that are chiefly responsible for the production and release of angiogenic factors, such as cytokines and other trophic factors. An increase in the vascularisation of a primary tumour can cause an increase in the number of cancer cells that enter into the circulation
15 and give rise to new metastases.

Recent studies have demonstrated that an increase in the density of microvessels in an area affected by neoplasia indicates new tumour growth.

It is therefore clinically important to suppress angiogenesis to inhibit its development, if possible. Indeed, by associating anti-angiogenic therapy with
20 "classic" anticancer therapy with drugs and/or radiation, with or without surgical removal of the tumour, it is possible to halt the proliferation of cancer cells, thus preventing the invasion of further tissues by said cells, and the consequent development of new metastases (Skobe H. et al., Nature Medicine, 1222-1227 (1997)).

25 In histological assessment of the onset of the angiogenic process

associated with a cancerous growth, it is important to look for markers of the tumour's vascular system, for example with antibodies that differentiate the endothelial cells from the cancerous ones. For example, the anti-CD3 antibody is specific for marking the endothelial cells and therefore enables their
5 identification in the angiogenic process associated with the development of new metastases. Its use has proved essential in assessing the level of microvessel development associated with neoplasia. Indeed, thanks to antibody marking, it is possible to visualise and count the number of interconnections of the vessels within the cancerous tissue to understand and
10 quantify the angiogenic process, relating it to any new developments in the neoplasia (thereby deciding if/how much/how to associate a therapy that modulates or inhibits angiogenesis with an established/classic anticancer therapy.

One such therapy consists in administering drugs that act by blocking
15 the receptors of the trophic factors (PGDF, bFGF, VEGF) that are also angiogenic factors.

Preclinical results 'in vivo' have shown that said drugs prove important in inhibiting tumour growth but they do not determine regression of the tumour itself: on the strength of these major experimental data, the drugs have
20 been introduced in numerous clinical trials.

However, an anti-angiogenic clinical therapy that provides for a generally oral pharmacological administration in chronic form may have many toxic side effects, because angiogenesis is not only associated with pathological disorders but also physiological processes such as tissue
25 reproduction and repair ("*Cancer: Principle Practice of Oncology*" V. De Vita, S. Hellmann and S. Rosenberg, 6th Edition).

It is therefore of strategic importance to associate classic anticancer therapy with an anti-angiogenic therapy "in situ", and this is the subject of the

present invention.

Hyaluronic acid is one of the chief components of the extracellular matrix of the connective tissue, and there are numerous scientific publications concerning its role in various processes, both physiological and pathological, such as the formation of granulation tissue, chemotaxis in the inflammatory process, cell differentiation for various cell types. Other studies concern its role within the family of "substrate adhesion molecules".

Hyaluronic acid has been used for the above indications:

- as a differentiating agent in therapy for acute myeloid leukaemia (Charrad R. S. et al., *Nature Medicine* 5, 669-676 (1999));
- as a vehicle for drugs such as steroids or NSAIDs, antibiotics and anti-neoplastic agents, because of the abundant expression of its receptor (CD44) in cancer cells; (Freemantle, C. et al., *Int. J. Tiss. Reac.* XVIII (4) 157-166 (1995); Coradini, D. et al., *Int. J. Cancer* 5, 411-416 (1999));
- in preclinical studies on the inhibition of lung metastasis, because of its capacity for inhibiting the adhesion of cancer cells to the vascular endothelium (Karasaza K. et al., *Clinical & Experimental Metastasis* 15, 83-93 (1997));
- as a means of controlling adhesion to the substrate with subsequent proliferation of cells (possibly also cancer cells) permanently "in situ" after surgical removal of tissues (including tumours) (U.S. 5,627,162).

Experimental observations "in vivo" have, however, revealed that hyaluronic acid may have a chemotaxic activity on cancer cells within the granulation tissue that forms after removal of cutaneous metastasis of melanoma (Salmon-Ehr, V. et al., *Ann. Dermatol. Venereol.* 123, 194-195 (1996)). Moreover, numerous pre-clinical studies have demonstrated that

hyaluronic acid enhances cancer cell migration, thereby favouring metastasis, as it is known that the degradation products of hyaluronic acid, that is, oligosaccharides constituted by 10 and 20 oligomers, are strong inducers of the angiogenic process (Hayen et al., J. Cell. Sci. 112, 2241-2251 (1999);
5 Slevin, M. et al., Lab. Invest. 78(8), 987-1003 (1998)).

Moreover, biomaterials based on hyaluronic acid and/or the derivatives thereof have never been used as an anti-angiogenic therapy, neither have any other biodegradable and/or non-biodegradable biopolymers ever been used in anticancer therapies.

10 Absolutely innovative, therefore, is the use of biomaterials based on hyaluronic acid derivatives such as Hyaff® (EP 0 216 453 B1) or ACPs (EP 0 341 745 B1) in the form of non-woven felts for instance (EP0 618 817 B1) or as three-dimensional structures (WO 99/61080), possibly in association with various biomaterials (e.g. natural ones such as collagen, cellulose,
15 polysaccharides, chitin, chitosan, pectin, agar, gellan and alginic acid, synthetic ones such as polylactic acid (PLA), polyglycolic acid (PGA), polyurethanes and polysulphonic resins, or semisynthetic ones such as collagen cross-linked with aldehyde, diamine and gellan) as a therapy to suppress and/or inhibit the angiogenic process that enhances and determines
20 tumour metastasis.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to biomaterials based on hyaluronic acid derivatives made into non-woven felts (as the preferred form of biomaterial), optionally in association with natural, synthetic or semisynthetic biopolymers,
25 for use in the medical-surgical field as a new anti-angiogenic therapy ("in situ"), optionally associated with classic pharmacological anticancer therapies and/or radiotherapy, to modulate indirectly the proliferation of tumours, thus blocking the formation of local relapses and, therefore, any new metastases.

In order to study, characterise and then assess “in vivo” the effect of the biomaterial of the present invention in the angiogenic process that supports the development of skin carcinomas (considered to be a clarifying example), the Applicant has developed a new model of tumour/ stromal cell support interaction, described as follows:

- 1) two cell lines of human keratinocytes transfected with the ras-oncogene: HCaT II-4, malignant variant and A5, benign variant;
- 2) said cells are transferred onto a collagen gel mounted into teflon rings covered by a silicone chamber, known as the Fusenig silicone chamber (FSC);
- 3) said FSC is then placed over the muscle fascia of the backs of nude mice, in the presence or absence of an immediately underlying layer of biomaterial based on Hyaff® 11 (total benzyl ester of hyaluronic acid) made in the form of a non-woven felt;
- 4) four to six weeks later, two different types of granulation tissue will have formed underneath the cancerous epithelium;
- 5) the development of the epithelial tumour and of the underlying granulation tissue is assessed, over time, both by classic histological analyses (haematoxylin/eosin) and by immunohistochemical techniques using the anti-CD31 antibody, to visualise the presence of vascular epithelium and therefore determine the development of the angiogenic process;
- 6) the levels of cellular proliferation are examined using immunohistochemical techniques associated with the introduction of BrdU into the DNA of proliferating cells, both within the granulation tissue underneath the epithelium and in the cancerous epithelium itself. Marking with the anti-integrin $\alpha 6$ antibody was also assessed to study the level of cellular proliferation within the

cancerous epithelium.

The results of the experiment were as follows:

HACaT A5 line:

After 4-6 weeks, the cancerous epithelium in the control FSC (i.e.
5 without any biomaterial placed under the epithelium), was well developed and
multilayered, while the layer of granulation tissue underneath had completely
replaced the layer of collagen that separated the epithelium from the
underlying tissue (Fig. 1).

Conversely, four weeks later, the cancerous epithelium in the FSC
10 placed over the Hyaff®-based biomaterial in the form of a non-woven felt is
less developed than the relative control, and the layer of collagen that
separates it from the nascent granulation tissue underneath is still thick and
not infiltrated by cells and/or vessels (Fig. 1).

After six weeks, the quantity of collagen is still abundant, with just an
15 initial layer of granulation tissue that begins to form over the biomaterial (Fig.
1).

HACaT II 4 line:

After four to six weeks, in the control FSC, the cancer cells have
constituted a thick epithelium that penetrates into the thickness of the new
20 granulation tissue underneath, that has already completely replaced the layer
of collagen that separated it from the epithelium (Fig. 2).

Four weeks later, in the FSC placed over the Hyaff®-based biomaterial,
the cancerous epithelium is thin but easily distinguishable from the
granulation tissue forming over the biomaterial, separated from this tissue by
25 the collagen gel that is still present and not yet absorbed (Fig. 2).

Six weeks later, the tumour mass and the granulation tissue have
established close contact, but there has been no actual infiltration of tumour
cells into the granulation tissue, unlike the control, where the tumour cells

have completely invaded the new, underlying granulation tissue (Fig. 2).

Using immunohistochemical techniques linked with the specific marking of particular nucleotides such as BrdU, at the 1st and 2nd weeks, good cell proliferation is evident within the nascent granulation tissue in the control
5 and in the Hyaff®-based biomaterial, while at 4, and especially at 6, weeks after transplant, the cell growth rate drops drastically in the granulation tissue underneath the cancerous epithelium, which conversely maintains in both samples a good level of cellular proliferation (Fig. 3).

The growth of cancerous epithelium can also be visualised with a
10 specific antibody against the protein integrin $\alpha 6$. Said molecule is, indeed, a component of the hemidesmosomes and its expression is normally only associated with the proliferative area of the epithelial layers.

Fig. 3a shows that antibody marking for the integrin protein $\alpha 6$ is notably present throughout the cancerous epithelium both in the control FCS
15 and in the FCS with the Hyaff®-based biomaterial, even though expression of the test protein appears less extensive throughout the thickness of the cancerous epithelium in the latter sample.

Specific marking for the vascular epithelium with the anti-CD31 antibody reveals, furthermore, that in the controls, after four weeks, the
20 angiogenic process is well established as the vessels in the underlying granulation tissue already reach the cancerous epithelium and after 6 weeks they invade it, thus favouring metastasis (Fig. 4).

In the case of the FSC with the Hyaff®-based biomaterial, after four weeks there is still no close contact between granulation tissue and cancerous
25 epithelium. This will occur only after six weeks, even though there is no invasion of the epithelium by the underlying microvessels, that remain relegated to the granulation tissue (Fig. 4).

The angiogenic process seems to be at a standstill, no longer enhancing

tumour development. Vascularisation is limited to the area covered by the Hyaff®-based biomaterial, so the tumour cells do not invade the granulation tissue that has formed within the biomaterial.

In conclusion, the Hyaff®-based biomaterial proved able to modulate/inhibit the angiogenic process related to vascularisation of the cancerous epithelium. It therefore proves to be particularly advantageous to use the biomaterials based on hyaluronic acid derivatives in the oncological field, where it is important to modulate the angiogenic process and therefore, indirectly, the proliferation of cancer cells in primary and secondary tumours.

According to the invention, the biomaterials that can be useful in the oncological field as a new anti-angiogenic therapy "in situ" may be, for example, in the form of non-woven felts, sponges, films, membranes, microspheres or in other three-dimensional forms in cases where it is necessary to fill the cavities that are liable to form after surgical removal of a tumour.

The anti-angiogenic action of the biomaterial can, moreover, be supported by supplementing the biomaterial with NSAIDs, steroids, hormones, antibiotics and especially anti-cancer drugs such as fluorouracil, methotrexate, cis-platinum, carboplatin, oxaliplatin, ethopoxide, cyclophosphamide, vincristine, doxorubicin.


The invention being thus described, it is clear that these methods can be modified in various ways. Said modifications are not to be considered as divergences from the spirit and purposes of the invention and any modification that would appear evident to an expert in the field comes within the scope of the following claims.

CLAIMS:

1. Use of hyaluronic acid benzyl ester for the preparation of a biomaterial suitable for antiangiogenic therapy to treat primary and secondary tumours.
2. The use according to claim 1 wherein hyaluronic acid is in association with other natural, synthetic and/or semisynthetic biopolymers.
3. The use according to claim 2, wherein the natural biopolymer is selected from the group consisting of collagen, cellulose, polysaccharides, chitin, chitosan, pectins, agar, gellan and alginic acid.
4. The use according to claim 2, wherein the synthetic biopolymer is selected from the group consisting of polylactic acid (PLA), polyglycolic acid (PGA), polyurethanes and polysulphonic resins.
5. The use according to claim 2, wherein the semisynthetic biopolymer is selected from the group consisting of collagen cross-linked with aldehydes, diamine and gellan.
6. The use according to claim 1 wherein the biomaterial is in association with pharmacologically active substances.
7. The use according to claim 6, wherein the pharmacologically active substance is selected from the group consisting of fluorouracil, methotrexate, cis-platinum, carboplatin, oxaliplatin, ethopoxide, cyclophosphamide, vincristine, doxorubicin.
8. The use according to any one of claims 1-7 wherein the biomaterial is in the form of a non-woven felt, sponge, microsphere, film or membrane and/or other three-dimensional structures.
9. The use according to any one of claims 1-8, for the treatment and care of primary and secondary tumours when the tumour has been surgically removed and the cavity that is thus formed requires filling.

1/5


A5



A5 Hyaff 11



4



6





Fig. 1

2/5


II-4



II-4 Hyaff 11



4



6






Fig. 2



3/5

II-4



II-4 Hyaff 11





1



2




4




6

Fig. 3

6



4



II-4


II-4 Hyaff 11

Fig. 3a



5/5

II-4

II-4 Hyaff 11



4



6

Fig. 4